

Data Sharing Statement

Article Info	https://dx.doi.org/10.21037/jtd-21-1022	
Item	Question	Authors' Response (place “-” if not applicable)
1	Would you like to share data collected for your study to others?	Yes
2	If not, would you like to share the reason for your decision?	-
3	What data in particular will be shared?	The efficacy and safety information of enrolled patients.
4	Any other documents will be share? Such as study protocol, statistical analysis plan, informed consent form, clinical study report, analytic code.	-
5	When will data availability begin?	From the publication date.
6	When will data availability end?	No limit.
7	To whom will you share the data?	Medical oncologists and lung surgeons who are interested in this study.
8	For what type of analysis or purpose?	For analysis to evaluate the efficacy and safety of neoadjuvant therapy with the PD-1 inhibitor camrelizumab, nab-paclitaxel, and carboplatin for patients with stage IB-III A NSCLC and to establish a multi-omics artificial intelligence system for neoadjuvant therapy based on radiomics, metabolism, and genetic and clinic-pathological characteristics.
9	How or where can the data/ documents be obtained?	Emails could be sent to the address below to obtain the shared data: yaoherui@mail.sysu.edu.cn
10	Any other restrictions?	We may balance the potential benefits and risks for each request and then provide the data that could be shared.